AU2014305430B2 - Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof - Google Patents

Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof Download PDF

Info

Publication number: AU2014305430B2
Authority: AU; Australia
Prior art keywords: polymer; andrographolide; drug; enteric; plasticizer
Prior art date: 2013-08-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU2014305430A

Other languages

English (en)

Other versions

AU2014305430A1 (en

Inventor

Zhixin Guo

Sen Lin

Xiaohui Ma

Henry Sun

Genbei Wang

Lulu YAN

Lihua Zhang

Shunnan Zhang

Shuiping Zhou

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Tasly Pharmaceutical Group Co Ltd

Original Assignee

Tasly Pharmaceutical Group Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-08-06

Filing date

2014-08-06

Publication date

2019-02-07

2014-08-06 Application filed by Tasly Pharmaceutical Group Co Ltd filed Critical Tasly Pharmaceutical Group Co Ltd

2016-03-03 Publication of AU2014305430A1 publication Critical patent/AU2014305430A1/en

2019-02-07 Application granted granted Critical

2019-02-07 Publication of AU2014305430B2 publication Critical patent/AU2014305430B2/en

Status Ceased legal-status Critical Current

2034-08-06 Anticipated expiration legal-status Critical

Links

BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 title claims abstract description 202
ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 title claims abstract description 201
238000002360 preparation method Methods 0.000 title claims abstract description 54
230000008685 targeting Effects 0.000 title claims abstract description 54
238000000034 method Methods 0.000 title claims abstract description 37
208000022559 Inflammatory bowel disease Diseases 0.000 title claims abstract description 28
229920000642 polymer Polymers 0.000 claims description 250
239000010410 layer Substances 0.000 claims description 205
239000003814 drug Substances 0.000 claims description 157
229940079593 drug Drugs 0.000 claims description 145
239000008188 pellet Substances 0.000 claims description 136
239000003795 chemical substances by application Substances 0.000 claims description 131
239000004014 plasticizer Substances 0.000 claims description 122
239000002702 enteric coating Substances 0.000 claims description 114
238000009505 enteric coating Methods 0.000 claims description 114
239000011248 coating agent Substances 0.000 claims description 80
238000000576 coating method Methods 0.000 claims description 80
210000001072 colon Anatomy 0.000 claims description 75
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 56
230000000968 intestinal effect Effects 0.000 claims description 50
230000004584 weight gain Effects 0.000 claims description 48
235000019786 weight gain Nutrition 0.000 claims description 48
208000011231 Crohn disease Diseases 0.000 claims description 46
206010009900 Colitis ulcerative Diseases 0.000 claims description 42
201000006704 Ulcerative Colitis Diseases 0.000 claims description 42
229920003145 methacrylic acid copolymer Polymers 0.000 claims description 34
239000004094 surface-active agent Substances 0.000 claims description 32
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 30
238000010907 mechanical stirring Methods 0.000 claims description 29
239000000546 pharmaceutical excipient Substances 0.000 claims description 28
238000003756 stirring Methods 0.000 claims description 28
239000000203 mixture Substances 0.000 claims description 27
238000009472 formulation Methods 0.000 claims description 25
238000011068 loading method Methods 0.000 claims description 24
239000000463 material Substances 0.000 claims description 24
239000007921 spray Substances 0.000 claims description 22
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical group CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 18
FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical group O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 16
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 16
238000010008 shearing Methods 0.000 claims description 16
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 14
229930006000 Sucrose Natural products 0.000 claims description 14
239000005720 sucrose Substances 0.000 claims description 14
238000005303 weighing Methods 0.000 claims description 14
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 13
239000002775 capsule Substances 0.000 claims description 13
238000010438 heat treatment Methods 0.000 claims description 13
230000002572 peristaltic effect Effects 0.000 claims description 11
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 9
229940075507 glyceryl monostearate Drugs 0.000 claims description 9
239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 9
239000001069 triethyl citrate Substances 0.000 claims description 9
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 9
235000013769 triethyl citrate Nutrition 0.000 claims description 9
239000008187 granular material Substances 0.000 claims description 8
239000004615 ingredient Substances 0.000 claims description 8
239000003960 organic solvent Substances 0.000 claims description 8
206010023799 Large intestinal ulcer Diseases 0.000 claims description 7
230000003247 decreasing effect Effects 0.000 claims description 7
201000010099 disease Diseases 0.000 claims description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims description 6
230000002008 hemorrhagic effect Effects 0.000 claims description 6
230000002757 inflammatory effect Effects 0.000 claims description 6
ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims description 6
230000008961 swelling Effects 0.000 claims description 6
230000008719 thickening Effects 0.000 claims description 6
229920001477 hydrophilic polymer Polymers 0.000 claims description 4
239000000049 pigment Substances 0.000 claims description 4
239000008063 pharmaceutical solvent Substances 0.000 claims description 2
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
239000000243 solution Substances 0.000 description 83
NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 25
241000700159 Rattus Species 0.000 description 25
241000699670 Mus sp. Species 0.000 description 24
239000013641 positive control Substances 0.000 description 22
241000252212 Danio rerio Species 0.000 description 19
230000000694 effects Effects 0.000 description 19
241001465754 Metazoa Species 0.000 description 18
206010061218 Inflammation Diseases 0.000 description 17
230000004054 inflammatory process Effects 0.000 description 15
210000001519 tissue Anatomy 0.000 description 15
230000037396 body weight Effects 0.000 description 14
GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 14
230000006378 damage Effects 0.000 description 13
208000035861 hematochezia Diseases 0.000 description 13
230000002829 reductive effect Effects 0.000 description 13
239000003826 tablet Substances 0.000 description 13
229920003134 Eudragit® polymer Polymers 0.000 description 12
208000027418 Wounds and injury Diseases 0.000 description 12
BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 12
230000001419 dependent effect Effects 0.000 description 12
238000002474 experimental method Methods 0.000 description 12
208000014674 injury Diseases 0.000 description 12
229920003135 Eudragit® L 100-55 Polymers 0.000 description 11
210000001035 gastrointestinal tract Anatomy 0.000 description 11
239000007788 liquid Substances 0.000 description 11
230000001225 therapeutic effect Effects 0.000 description 11
231100000397 ulcer Toxicity 0.000 description 11
206010012735 Diarrhoea Diseases 0.000 description 10
239000008186 active pharmaceutical agent Substances 0.000 description 10
230000002354 daily effect Effects 0.000 description 10
208000025865 Ulcer Diseases 0.000 description 9
210000000440 neutrophil Anatomy 0.000 description 9
230000000144 pharmacologic effect Effects 0.000 description 9
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 9
208000024891 symptom Diseases 0.000 description 9
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
229920003141 Eudragit® S 100 Polymers 0.000 description 8
239000013078 crystal Substances 0.000 description 8
210000001015 abdomen Anatomy 0.000 description 7
206010009887 colitis Diseases 0.000 description 7
210000001198 duodenum Anatomy 0.000 description 7
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 7
229960005205 prednisolone Drugs 0.000 description 7
210000002784 stomach Anatomy 0.000 description 7
239000000725 suspension Substances 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
208000002193 Pain Diseases 0.000 description 6
241001098657 Pterois Species 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
238000007796 conventional method Methods 0.000 description 6
238000004090 dissolution Methods 0.000 description 6
238000011156 evaluation Methods 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
230000034994 death Effects 0.000 description 5
210000003608 fece Anatomy 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
210000004379 membrane Anatomy 0.000 description 5
239000012528 membrane Substances 0.000 description 5
150000002772 monosaccharides Chemical class 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
238000011160 research Methods 0.000 description 5
YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 4
244000118350 Andrographis paniculata Species 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
230000008859 change Effects 0.000 description 4
238000012377 drug delivery Methods 0.000 description 4
239000000945 filler Substances 0.000 description 4
210000004347 intestinal mucosa Anatomy 0.000 description 4
KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 4
229960004963 mesalazine Drugs 0.000 description 4
210000000813 small intestine Anatomy 0.000 description 4
239000000829 suppository Substances 0.000 description 4
VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
241000251468 Actinopterygii Species 0.000 description 3
206010057669 Colon injury Diseases 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 3
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
210000000436 anus Anatomy 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000035622 drinking Effects 0.000 description 3
UJKWLAZYSLJTKA-UHFFFAOYSA-N edma Chemical compound O1CCOC2=CC(CC(C)NC)=CC=C21 UJKWLAZYSLJTKA-UHFFFAOYSA-N 0.000 description 3
235000013305 food Nutrition 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
210000003405 ileum Anatomy 0.000 description 3
230000008595 infiltration Effects 0.000 description 3
238000001764 infiltration Methods 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
230000000877 morphologic effect Effects 0.000 description 3
230000017074 necrotic cell death Effects 0.000 description 3
239000012188 paraffin wax Substances 0.000 description 3
238000005070 sampling Methods 0.000 description 3
238000002791 soaking Methods 0.000 description 3
235000002639 sodium chloride Nutrition 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
229960001940 sulfasalazine Drugs 0.000 description 3
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 3
238000012360 testing method Methods 0.000 description 3
MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 2
DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 2
208000004998 Abdominal Pain Diseases 0.000 description 2
208000002881 Colic Diseases 0.000 description 2
206010013183 Dislocation of vertebra Diseases 0.000 description 2
244000020551 Helianthus annuus Species 0.000 description 2
235000003222 Helianthus annuus Nutrition 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
241000212749 Zesius chrysomallus Species 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000000112 colonic effect Effects 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
230000010339 dilation Effects 0.000 description 2
230000009266 disease activity Effects 0.000 description 2
238000004821 distillation Methods 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
229930004069 diterpene Natural products 0.000 description 2
-1 diterpene lactone compound Chemical class 0.000 description 2
239000012467 final product Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000003862 glucocorticoid Substances 0.000 description 2
230000028993 immune response Effects 0.000 description 2
239000003018 immunosuppressive agent Substances 0.000 description 2
229940125721 immunosuppressive agent Drugs 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
238000001543 one-way ANOVA Methods 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
231100000915 pathological change Toxicity 0.000 description 2
230000036285 pathological change Effects 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000011148 porous material Substances 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
210000000664 rectum Anatomy 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
238000013077 scoring method Methods 0.000 description 2
210000001599 sigmoid colon Anatomy 0.000 description 2
230000007480 spreading Effects 0.000 description 2
238000003892 spreading Methods 0.000 description 2
238000010186 staining Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
229940032147 starch Drugs 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
230000002792 vascular Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
BJFIDCADFRDPIO-DZCXQCEKSA-N (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(phenylmethyl)-1,2-dithia-5,8,11,14,17-pentazacycloeicos-4-yl]-oxomethyl]-2-pyrrolidinecarboxamide Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1 BJFIDCADFRDPIO-DZCXQCEKSA-N 0.000 description 1
241000207965 Acanthaceae Species 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
208000019399 Colonic disease Diseases 0.000 description 1
241001605679 Colotis Species 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
241000792859 Enema Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
229920003136 Eudragit® L polymer Polymers 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
206010017367 Frequent bowel movements Diseases 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
208000008081 Intestinal Fistula Diseases 0.000 description 1
208000032177 Intestinal Polyps Diseases 0.000 description 1
206010022699 Intestinal stenosis Diseases 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
108010048179 Lypressin Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
206010057071 Rectal tenesmus Diseases 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
108010010056 Terlipressin Proteins 0.000 description 1
FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
230000003044 adaptive effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
230000001668 ameliorated effect Effects 0.000 description 1
239000003708 ampul Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001775 anti-pathogenic effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000003124 biologic agent Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
210000004921 distal colon Anatomy 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000012154 double-distilled water Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940095399 enema Drugs 0.000 description 1
239000002662 enteric coated tablet Substances 0.000 description 1
230000008556 epithelial cell proliferation Effects 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
208000027686 extensive ulcer Diseases 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
230000009477 glass transition Effects 0.000 description 1
210000002175 goblet cell Anatomy 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
230000003862 health status Effects 0.000 description 1
239000012676 herbal extract Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000036732 histological change Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
229960000598 infliximab Drugs 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
210000005027 intestinal barrier Anatomy 0.000 description 1
230000004673 intestinal mucosal barrier function Effects 0.000 description 1
208000003243 intestinal obstruction Diseases 0.000 description 1
230000001788 irregular Effects 0.000 description 1
210000001630 jejunum Anatomy 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
229960003837 lypressin Drugs 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
244000005700 microbiome Species 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
230000001314 paroxysmal effect Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000008855 peristalsis Effects 0.000 description 1
239000002861 polymer material Substances 0.000 description 1
229920005597 polymer membrane Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000004223 radioprotective effect Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
238000001223 reverse osmosis Methods 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
238000007789 sealing Methods 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000007779 soft material Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000001148 spastic effect Effects 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000002563 stool test Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
208000012271 tenesmus Diseases 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
229920003176 water-insoluble polymer Polymers 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
229940126673 western medicines Drugs 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
- B01J2/006—Coating of the granules without description of the process or the device by which the granules are obtained

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AU2014305430A 2013-08-06 2014-08-06 Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof Ceased AU2014305430B2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
CN201310338444.1		2013-08-06
CN201310338444		2013-08-06
PCT/CN2014/083810 WO2015018344A1 (zh)	2013-08-06	2014-08-06	穿心莲内酯在制备炎症性肠病的药物中的应用、穿心莲内酯肠溶靶向微丸及其制备方法

Publications (2)

Publication Number	Publication Date
AU2014305430A1 AU2014305430A1 (en)	2016-03-03
AU2014305430B2 true AU2014305430B2 (en)	2019-02-07

Family

ID=52460670

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2014305430A Ceased AU2014305430B2 (en)	2013-08-06	2014-08-06	Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof

Country Status (13)

Country	Link
US (3)	US9889093B2 (ru)
EP (1)	EP3031456A4 (ru)
JP (1)	JP6389889B2 (ru)
KR (1)	KR20160040697A (ru)
CN (2)	CN104337773B (ru)
AU (1)	AU2014305430B2 (ru)
CA (1)	CA2920533A1 (ru)
HK (1)	HK1220909A1 (ru)
MY (1)	MY176758A (ru)
PH (1)	PH12016500258A1 (ru)
RU (1)	RU2681930C2 (ru)
SG (1)	SG11201600933QA (ru)
WO (1)	WO2015018344A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN105030764B (zh) *	2015-06-15	2019-04-19	广州喜鹊医药有限公司	穿心莲内酯衍生物在制备治疗炎症性肠病药物中的应用
CN110420179A (zh) *	2019-08-12	2019-11-08	韩育娟	一种炎琥宁干混悬剂及其制备方法
KR102104507B1 (ko) *	2019-08-23	2020-04-24	브릿지바이오테라퓨틱스(주)	팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법
CN110585138B (zh) *	2019-09-29	2021-08-03	黑龙江中医药大学	穿心莲颗粒及其制备方法
IT201900017555A1 (it) *	2019-09-30	2021-03-30	Dymalife Res S R L	Associazione per uso nel trattamento e prevenzione di disturbi infiammatori del tratto intestinale
CN113116862B (zh) *	2019-12-30	2022-05-27	辽宁上药好护士药业（集团）有限公司	一种瘀血痹微丸及其制备方法和应用
WO2022047730A1 (en)	2020-09-04	2022-03-10	Shanghai Pharmaceuticals Holding Co., Ltd.	Methods to treat inflammatory bowel disease
CN112245596B (zh) *	2020-11-09	2022-01-18	浙江大学	一种基于斑马鱼炎症性肠病模型筛选药效物质的方法
CN113069429A (zh) *	2021-04-07	2021-07-06	临沂大学	一种装载芍药苷的透明质酸修饰埃洛石纳米管/壳聚糖肠溶包衣微球及其制备方法
CN116326537A (zh) *	2021-12-22	2023-06-27	成都海枫生物科技有限公司	一种大鼠克罗恩病模型的构建方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001066094A1 (en) *	2000-03-07	2001-09-13	Pharmatec International S.R.L.	Controlled release oral solid forms containing mesalazine as active agent
CN101422494A (zh) *	2007-11-02	2009-05-06	和记黄埔医药（上海）有限公司	一种穿心莲提取物及其医药用途
CN102614133A (zh) *	2012-04-10	2012-08-01	沈阳药科大学	穿心莲内酯研磨悬浮液及其制备方法和药物制剂的应用
CN103070843A (zh) *	2013-01-16	2013-05-01	司鹏	一种含有炎琥宁的口服制剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5843479A (en) *	1993-02-26	1998-12-01	The Procter & Gamble Company	Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) *	1993-02-26	1999-06-22	The Procter & Gamble Company	Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
ES2241478B1 (es) *	2004-02-13	2006-11-16	Lacer S.A.	Preparacion farmaceutica para la liberacion sostenida de un principio farmaceuticamente activo.
KR20070049103A (ko) *	2004-03-11	2007-05-10	허치슨 메디파르마 리미티드	ＴＮＦα 및 ＩＬ-1β 발현 억제제로서 안드로그라폴라이드및 유사체
CN1689628B (zh) *	2004-04-29	2010-04-21	和记黄埔医药企业有限公司	穿心莲提取物的医药用途
CN1969895A (zh) *	2005-11-22	2007-05-30	徐小彬	穿心莲肠溶制剂及制备方法
CN1981743A (zh)	2005-12-13	2007-06-20	珠海天翼医药技术开发有限公司	一种结肠定位释放微丸及其制备方法
WO2008059522A2 (en) *	2006-09-28	2008-05-22	Unijules Life Sciences Ltd	Herbal gastrointenstinal controlled drug delivery dosage forms including pellets and process for their preparation
CN101209246A (zh)	2006-12-29	2008-07-02	天津医科大学	一种新型pH依赖型结肠定位释药系统
US20090117209A1 (en) *	2007-11-02	2009-05-07	Hutchison Medipharma Enterprises Limited	Andrographis paniculata extract
WO2011025673A1 (en) *	2009-08-26	2011-03-03	Aptapharma, Inc.	Multilayer minitablets
CN102552171B (zh) *	2012-03-02	2016-03-09	北京科信必成医药科技发展有限公司	一种穿心莲内酯结肠定位微丸及其制备方法
CN102579363B (zh) *	2012-03-02	2016-03-09	北京科信必成医药科技发展有限公司	一种结肠定位释药的微丸及其制备方法
CN103315959B (zh)	2012-03-21	2015-05-06	上海市第一人民医院	一种治疗炎症性肠病的口服结肠靶向制剂及其制备方法
CN103908535A (zh) *	2014-03-19	2014-07-09	锦州博泽医药科技开发有限公司	一种含有穿心莲内酯的肠溶胶囊

2014
- 2014-08-06 SG SG11201600933QA patent/SG11201600933QA/en unknown
- 2014-08-06 KR KR1020167005980A patent/KR20160040697A/ko not_active Abandoned
- 2014-08-06 WO PCT/CN2014/083810 patent/WO2015018344A1/zh active Application Filing
- 2014-08-06 US US14/910,173 patent/US9889093B2/en active Active
- 2014-08-06 AU AU2014305430A patent/AU2014305430B2/en not_active Ceased
- 2014-08-06 CN CN201410386505.6A patent/CN104337773B/zh active Active
- 2014-08-06 MY MYPI2016700447A patent/MY176758A/en unknown
- 2014-08-06 CA CA2920533A patent/CA2920533A1/en not_active Abandoned
- 2014-08-06 RU RU2016107440A patent/RU2681930C2/ru active
- 2014-08-06 JP JP2016532228A patent/JP6389889B2/ja active Active
- 2014-08-06 EP EP14835361.8A patent/EP3031456A4/en active Pending
- 2014-08-06 CN CN201480044529.1A patent/CN105451734A/zh active Pending
2016
- 2016-02-05 PH PH12016500258A patent/PH12016500258A1/en unknown
- 2016-07-28 HK HK16109062.6A patent/HK1220909A1/zh unknown
2017
- 2017-03-27 US US15/469,711 patent/US20170224623A1/en not_active Abandoned
- 2017-03-27 US US15/469,834 patent/US20170224622A1/en not_active Abandoned

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001066094A1 (en) *	2000-03-07	2001-09-13	Pharmatec International S.R.L.	Controlled release oral solid forms containing mesalazine as active agent
CN101422494A (zh) *	2007-11-02	2009-05-06	和记黄埔医药（上海）有限公司	一种穿心莲提取物及其医药用途
CN102614133A (zh) *	2012-04-10	2012-08-01	沈阳药科大学	穿心莲内酯研磨悬浮液及其制备方法和药物制剂的应用
CN103070843A (zh) *	2013-01-16	2013-05-01	司鹏	一种含有炎琥宁的口服制剂及其制备方法

Also Published As

Publication number	Publication date
US20160175253A1 (en)	2016-06-23
RU2016107440A3 (ru)	2018-05-03
RU2681930C2 (ru)	2019-03-14
RU2016107440A (ru)	2017-09-15
SG11201600933QA (en)	2016-03-30
JP2016527281A (ja)	2016-09-08
PH12016500258A1 (en)	2016-05-16
HK1220909A1 (zh)	2017-05-19
CN104337773A (zh)	2015-02-11
WO2015018344A1 (zh)	2015-02-12
MY176758A (en)	2020-08-21
CN105451734A (zh)	2016-03-30
EP3031456A1 (en)	2016-06-15
CN104337773B (zh)	2018-11-30
US20170224623A1 (en)	2017-08-10
US20170224622A1 (en)	2017-08-10
JP6389889B2 (ja)	2018-09-12
AU2014305430A1 (en)	2016-03-03
EP3031456A4 (en)	2016-12-28
CA2920533A1 (en)	2015-02-12
KR20160040697A (ko)	2016-04-14
US9889093B2 (en)	2018-02-13

Publication	Publication Date	Title
AU2014305430B2 (en)	2019-02-07	Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof
CN107929718A (zh)	2018-04-20	Glp‑1类似物及gc‑c受体激动剂组合物缓释制剂及其制备方法
KR20160025524A (ko)	2016-03-08	크론병의 예방 및/또는 치료를 위한 약제 제조에 있어서의 중의약 제제의 용도
US20230263740A1 (en)	2023-08-24	Capsule for treating ulcerative colitis
CN108888670B (zh)	2022-03-04	一种治疗溃疡性结肠炎的结肠靶向胶囊剂及其制备工艺
CN108175849B (zh)	2021-08-27	聚普瑞锌口服制剂及在制备溃疡性结肠炎药物中的应用
CN113546089B (zh)	2023-04-28	1-乙基-3，7-二甲基黄嘌呤在制备治疗肺炎药物中的应用
CN101756955B (zh)	2012-09-05	知母宁复合物及其制备方法和应用
CN110038002B (zh)	2022-09-16	丹酚酸a防治肌肉萎缩、肌病及肌肉骨骼并发症的用途
CN104095843B (zh)	2018-03-20	牛蒡子苷元在制备治疗消化道溃疡性疾病药物中的应用
CN103655545B (zh)	2016-03-02	棕矢车菊素在制备治疗或预防慢性肾损伤的药物中的应用
CN101224212A (zh)	2008-07-23	阿魏酸及其钠盐用于制备预防和治疗抑郁症的药物
CN111529528A (zh)	2020-08-14	一种治疗溃疡性结肠炎的药物组合物
CN119607017A (zh)	2025-03-14	曲拉在制备治疗溃疡性结肠炎产品中的应用
WO2022162649A1 (en)	2022-08-04	Delayed release composition comprising enteric coated drug loaded in psyllium husk matrix
CN118436644A (zh)	2024-08-06	附子灵在制备治疗溃疡性结肠炎药物中的应用
CN119499258A (zh)	2025-02-25	人参二醇在制备预防和/或治疗帕金森病药物中的应用
KR20250024807A (ko)	2025-02-19	플로로글루시놀 제제 및 사용 방법
CN119185483A (zh)	2024-12-27	温郁金提取物及其灌肠剂在治疗溃疡性结肠炎中的应用
CN104490912A (zh)	2015-04-08	升麻素苷作为制备预防和治疗肝损伤性疾病药物的应用
CN107158095A (zh)	2017-09-15	一种三黄肠溶给药组合物及其制备方法
CN118615340A (zh)	2024-09-10	芹槐提取物用于预防或治疗肝病的用途
CN107157987A (zh)	2017-09-15	含氮的天然产物的医药用途
CN1985955A (zh)	2007-06-27	一种畜禽使用的两性霉素b白芨胶生物粘附缓释胶囊
CN1985953A (zh)	2007-06-27	一种畜禽使用的氧氟沙星白芨胶生物粘附缓释胶囊

Legal Events

Date	Code	Title	Description
2019-06-06	FGA	Letters patent sealed or granted (standard patent)
2023-03-02	MK14	Patent ceased section 143(a) (annual fees not paid) or expired